FDA approves Abrysvo for immunization at 32 through 36 weeks gestational age of pregnancy to prevent lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age.
FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants
FDA approves Abrysvo for immunization at 32 through 36 weeks gestational age of pregnancy to prevent lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age.
Niura's EEG-implemented earbuds scan your brain health and recommend music to your mood
Family of Black man who died while restrained in a mental health facility agrees to $8.5 million settlement
Lachlan Murdoch’s On-Again, Off-Again Relationship With the Family Business
Duke Health chief data scientist Michael Pencina talks intersection of AI and healthcare
